Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Sell

Analyst Rating

Neutral

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

Regulus Therapeutics Inc. (RGLS)

Pharmaceutical Preparations

https://www.regulusrx.com

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes.

4224 CAMPUS POINT COURT, SUITE 210
SAN DIEGO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/04/2012

Market Cap

102,860,022

Shares Outstanding

20,220,000

Weighted SO

20,222,672

Total Employees

N/A

Upcoming Earnings

08/13/2024

Similar Tickers

INFI --.--%

TENX --.--%

VSTM --.--%

PULM --.--%

CLRB --.--%

Beta

1.6210

Last Div

0.0000

Range

1.08-3.79

Chg

-0.0188

Avg Vol

841020

Mkt Cap

102860022

Exch

NASDAQ

Country

US

Phone

858 202 6300

DCF Diff

0.4768

DCF

1.0932

Div Yield

0.0000

P/S

340.5961

EV Multiple

-2.3322

P/FV

1.0316

Div Yield %

0.0000

P/E

-2.8620

PEG

-0.1901

Payout

0.0000

Current Ratio

18.4600

Quick Ratio

18.4600

Cash Ratio

3.2651

DSO

0.0000

DIO

0.0000

Op Cycle

0.0000

DPO

726.3742

CCC

-726.3742

Gross Margin

0.0000

Op Margin

-124.2086

Pretax Margin

-117.1821

Net Margin

-117.1854

Eff Tax Rate

0.0010

ROA

-0.3399

ROE

-0.5547

ROCE

-0.3795

NI/EBT

1.0000

EBT/EBIT

0.9434

EBIT/Rev

-124.2086

Debt Ratio

0.0137

D/E

0.0145

LT Debt/Cap

0.0068

Total Debt/Cap

0.0143

Int Coverage

231.5494

CF/Debt

-23.0527

Equity Multi

1.0605

Rec Turnover

0.0000

Pay Turnover

0.5025

Inv Turnover

0.0000

FA Turnover

0.1334

Asset Turnover

0.0029

OCF/Share

-0.5085

FCF/Share

-0.5228

Cash/Share

1.4662

OCF/Sales

-108.5464

FCF/OCF

1.0282

CF Coverage

-23.0527

ST Coverage

-43.8835

CapEx Coverage

-35.4773

Div&CapEx Cov

-35.4773

P/BV

1.0316

P/B

1.0316

P/S

340.5961

P/E

-2.8620

P/FCF

-3.0518

P/OCF

-3.0898

P/CF

-3.0898

PEG

-0.1901

P/S

340.5961

EV Multiple

-2.3322

P/FV

1.0316

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. May 15, 22:52 SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders

Revenue Product Segmentation